

Deok-Hwan Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8536525/publications.pdf>

Version: 2024-02-01

133
papers

1,970
citations

304743

22
h-index

302126

39
g-index

134
all docs

134
docs citations

134
times ranked

3209
citing authors

#	ARTICLE	IF	CITATIONS
1	Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL). <i>Cancer Research and Treatment</i> , 2023, 55, 304-313.	3.0	1
2	Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. <i>Cancer Research and Treatment</i> , 2023, 55, 325-333.	3.0	2
3	Diagnostic Accuracy and Prognostic Relevance of Immunoglobulin Heavy Chain Rearrangement and 18F-FDG-PET/CT Compared With Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Korean Medical Science</i> , 2022, 37, e2.	2.5	2
4	Relapse in patients with limited-stage ocular adnexal lymphoma treated by chemoimmunotherapy: Extended follow-up of a phase 2 study. <i>Cancer Medicine</i> , 2022, , .	2.8	4
5	Adrenal insufficiency in hospitalized patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 501-503.	1.3	2
6	Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1205-1208.	2.4	13
7	Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing. <i>Bone Marrow Transplantation</i> , 2021, 56, 1159-1170.	2.4	10
8	A combination of immunoadjuvant nanocomplexes and dendritic cell vaccines in the presence of immune checkpoint blockade for effective cancer immunotherapy. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1599-1601.	10.5	6
9	Clinical impact of cell-free serum Epstein-Barr virus status in patients with newly diagnosed malignant lymphoma. <i>Blood Research</i> , 2021, 56, 65-71.	1.3	1
10	Clinical characteristics and prognostic factors of acquired haemophilia A in Korea. <i>Haemophilia</i> , 2021, 27, e609-e616.	2.1	2
11	Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On 18F-FDG PET/CT at Baseline. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	1
12	Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment. <i>International Journal of Hematology</i> , 2021, 113, 668-674.	1.6	0
13	Variant Allele Frequency Status in Elderly Patients with Acute Myeloid Leukemia Can be Early Predictors of Responsiveness to Decitabine Treatment. <i>Blood</i> , 2021, 138, 3450-3450.	1.4	0
14	Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea. <i>Blood Research</i> , 2021, , .	1.3	3
15	Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. <i>Cancer Research and Treatment</i> , 2021, , .	3.0	4
16	Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report. <i>Annals of Hematology</i> , 2020, 99, 223-228.	1.8	6
17	Prognostic significance of FDG-PET/CT in determining upfront autologous stem cell transplantation for the treatment of peripheral T cell lymphomas. <i>Annals of Hematology</i> , 2020, 99, 83-91.	1.8	5
18	Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era. <i>Scientific Reports</i> , 2020, 10, 11649.	3.3	6

#	ARTICLE	IF	CITATIONS
19	Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2020, 9, 2310.	2.4	1
20	First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial. <i>Cancers</i> , 2020, 12, 2192.	3.7	16
21	Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma (CISL 12-09). <i>Annals of Hematology</i> , 2020, 99, 2831-2836.	1.8	3
22	Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. <i>BMC Cancer</i> , 2020, 20, 803.	2.6	18
23	RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia. <i>Scientific Reports</i> , 2020, 10, 20119.	3.3	6
24	Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma. <i>In Vivo</i> , 2020, 34, 2127-2134.	1.3	3
25	Frontline therapy for newly diagnosed patients with multiple myeloma. <i>Blood Research</i> , 2020, 55, S37-S42.	1.3	12
26	Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. <i>Yonsei Medical Journal</i> , 2020, 61, 452.	2.2	2
27	Phase II study of Râ€“CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. <i>Cancer Communications</i> , 2019, 39, 1-10.	9.2	12
28	Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma. <i>BMC Cancer</i> , 2019, 19, 59.	2.6	11
29	A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial). <i>Leukemia and Lymphoma</i> , 2019, 60, 3251-3257.	1.3	4
30	Remission clone in acute myeloid leukemia shows growth advantage after chemotherapy but is distinct from leukemic clone. <i>Experimental Hematology</i> , 2019, 75, 26-30.	0.4	1
31	¹⁸ F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 107-115.	6.4	34
32	Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 149-156.	0.4	2
33	Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party. <i>Annals of Hematology</i> , 2019, 98, 151-158.	1.8	18
34	Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era. <i>Blood</i> , 2019, 134, 4002-4002.	1.4	0
35	A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System. <i>British Journal of Haematology</i> , 2018, 181, 707-710.	2.5	12
36	Development of a UPLC-MS/MS method for the therapeutic monitoring of L-asparaginase. <i>Translational and Clinical Pharmacology</i> , 2018, 26, 134.	0.9	5

#	ARTICLE	IF	CITATIONS
37	Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e529-e535.	0.4	0
38	A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2274-2284.	6.4	8
39	Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2471-2478.	2.0	24
40	Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL). <i>BMC Cancer</i> , 2018, 18, 729.	2.6	6
41	Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype. <i>Oncotarget</i> , 2018, 9, 4961-4968.	1.8	19
42	The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 1169-1181.	1.7	5
43	18f-FDG PET/CT and the Revised International Staging System Are More Discriminating of Survival Outcomes in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 4483-4483.	1.4	0
44	STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma. <i>Blood Research</i> , 2017, 52, 293.	1.3	23
45	5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 8305-8314.	1.8	6
46	Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09). <i>Oncotarget</i> , 2017, 8, 13367-13374.	1.8	6
47	A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma. <i>Oncotarget</i> , 2017, 8, 41538-41548.	1.8	39
48	Tumor necrosis and complete resection has significant impacts on survival in patients with limited-stage upper aerodigestive tract NK/T cell lymphoma. <i>Oncotarget</i> , 2017, 8, 79337-79346.	1.8	8
49	Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study. <i>Oncotarget</i> , 2017, 8, 68583-68590.	1.8	15
50	Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 92171-92182.	1.8	12
51	Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional experience. <i>Radiation Oncology Journal</i> , 2017, 35, 317-324.	1.5	2
52	Salvage chemotherapy with R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) for the treatment of relapsed primary CNS lymphoma. <i>Blood Research</i> , 2016, 51, 285.	1.3	1
53	Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients. <i>Journal of Korean Medical Science</i> , 2016, 31, 1160.	2.5	8
54	Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression. <i>Annals of Hematology</i> , 2016, 95, 1645-1651.	1.8	4

#	ARTICLE	IF	CITATIONS
55	Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML. <i>Annals of Hematology</i> , 2016, 95, 625-635.	1.8	15
56	Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma. <i>Leukemia Research</i> , 2016, 49, 80-87.	0.8	9
57	Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. <i>BMC Cancer</i> , 2016, 16, 613.	2.6	24
58	Na ⁺ ve CD8+ T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF- β 2 immunosuppression in the tumor microenvironment. <i>Scientific Reports</i> , 2016, 6, 28208.	3.3	36
59	The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase. <i>Annals of Hematology</i> , 2016, 95, 1491-1501.	1.8	9
60	A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 389-400.	10.7	285
61	High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era. <i>Leukemia Research</i> , 2016, 42, 1-6.	0.8	49
62	Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study. <i>Annals of Hematology</i> , 2016, 95, 603-611.	1.8	7
63	Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. <i>Annals of Hematology</i> , 2016, 95, 301-310.	1.8	26
64	A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 1406-1412.	1.3	4
65	DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 61-70.	2.0	43
66	Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen. <i>Annals of Hematology</i> , 2016, 95, 55-61.	1.8	9
67	Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. <i>Oncotarget</i> , 2016, 7, 72033-72043.	1.8	14
68	Replication of New Genomic Classification System in Acute Myeloid Leukemia with Normal Karyotype. <i>Blood</i> , 2016, 128, 2876-2876.	1.4	0
69	A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-Cell Lymphoma (BENCART): A Consortium for Improving Survival of Lymphoma (CISL) Trial. <i>Blood</i> , 2016, 128, 1823-1823.	1.4	0
70	Phase 2 Study of Abbreviated 3 Cycles of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1 CD20+ Diffuse Large B-Cell Lymphoma (CISL 12-09). <i>Blood</i> , 2016, 128, 4193-4193.	1.4	0
71	Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype. <i>Haematologica</i> , 2015, 100, e351-e353.	3.5	31
72	Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 746-756.	1.4	160

#	ARTICLE	IF	CITATIONS
73	Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 1013-1020.	4.1	37
74	Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic. <i>Chonnam Medical Journal</i> , 2015, 51, 1.	0.9	27
75	Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. <i>Blood Research</i> , 2015, 50, 242.	1.3	15
76	Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma. <i>Chonnam Medical Journal</i> , 2015, 51, 109.	0.9	1
77	Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment. <i>Blood Research</i> , 2015, 50, 167.	1.3	1
78	Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. <i>Blood Research</i> , 2015, 50, 19.	1.3	24
79	Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. <i>BMC Cancer</i> , 2015, 15, 198.	2.6	28
80	Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1597-1604.	2.0	76
81	Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL). <i>European Journal of Haematology</i> , 2015, 94, 504-510.	2.2	16
82	Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 212.	1.7	27
83	Clinical significance of radiotherapy in the treatment of limited stage NK/T cell lymphoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 8549-8549.	1.6	0
84	5-Hydroxymethylcytosine Is Correlated with TET2 or IDH1/2 Mutations However, May Not be a Prognostic Value to Predict the Survivals in Normal Karyotype AML. <i>Blood</i> , 2015, 126, 3832-3832.	1.4	0
85	Discrepancy of Interim PET/CT Responses Based on Visual and Quantitative SUV-Based Assessments in the Patients with Diffuse Large B-Cell Lymphoma and Extranodal Involvements. <i>Blood</i> , 2015, 126, 1446-1446.	1.4	0
86	In the Novel Agents Era, Is the International Staging System Still Has the Prognostic Value in Patients with Renal Impairment?. <i>Blood</i> , 2015, 126, 5313-5313.	1.4	0
87	OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib. <i>Chonnam Medical Journal</i> , 2014, 50, 102.	0.9	25
88	Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	8
89	Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies: A Multicenter, Prospective, Open-Label, Observational Study in Korea. <i>Journal of Korean Medical Science</i> , 2014, 29, 61.	2.5	4
90	Polymorphisms in DNA Repair Genes and MDR1 and the Risk for Non-Hodgkin Lymphoma. <i>International Journal of Molecular Sciences</i> , 2014, 15, 6703-6716.	4.1	18

#	ARTICLE	IF	CITATIONS
91	The Impact of Hyperglycemia on Risk of Severe Infections during Early Period of Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-5.	1.9	17
92	Patterns of Relapse or Progression After Bortezomib-Based Salvage Therapy in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 389-394.	0.4	15
93	High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma Previously Treated with CHOP-based Chemotherapy: A Study from the Consortium for Improving Survival of Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 73-79.	2.0	17
94	Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. <i>Annals of Hematology</i> , 2013, 92, 471-479.	1.8	69
95	Serum Level Of Parathyroid Hormone Is Associated With Risk Factors and Clinical Outcomes In Multiple Myeloma. <i>Blood</i> , 2013, 122, 5365-5365.	1.4	1
96	Nilotinib Combined With Multi-Agent Chemotherapy For Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Final Results Of Prospective Multicenter Phase 2 Study. <i>Blood</i> , 2013, 122, 55-55.	1.4	4
97	<i>in vitro</i> induction of anterior gradient-2-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses as a potential therapy for colorectal cancer. <i>Experimental and Molecular Medicine</i> , 2012, 44, 60.	7.7	15
98	Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 807-811.	1.3	11
99	Lymphocytopenia Is Associated with an Increased Risk of Severe Infections in Patients with Multiple Myeloma Treated with Bortezomib-Based Regimens. <i>Blood</i> , 2012, 120, 5042-5042.	1.4	1
100	High Dose Etoposide Plus G-CSF As an Effective Mobilization Regimen in Patients with NHL Previously Treated with R-CHOP or CHOP Chemotherapy. Retrospective Multicenter Study. <i>Blood</i> , 2012, 120, 1917-1917.	1.4	0
101	A Modified Glasgow Prognostic Score (mGPS) Based On Systemic Inflammatory Response Is a Useful Indicator to Predict Response and Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2012, 120, 5089-5089.	1.4	1
102	Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2011, 47, 1312-1318.	2.8	82
103	Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins. <i>Annals of Hematology</i> , 2011, 90, 1419-1426.	1.8	13
104	Bortezomib Induction Followed by ASCT in Patients with Multiple Myeloma: Achievement of Response After Induction and Achieving CR Post-ASCT Are Both Important Prognostic Markers. <i>Blood</i> , 2011, 118, 1866-1866.	1.4	0
105	Potent Immunomodulatory Drug Lenalidomide Synergistically Enhance the Effect of Dendritic Cell Vaccination on Multiple Myeloma in Mouse Model. <i>Blood</i> , 2011, 118, 3237-3237.	1.4	0
106	Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells. <i>Annals of Hematology</i> , 2010, 89, 795-801.	1.8	25
107	Induction Treatment With Cyclophosphamide, Thalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Phase II Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 62-67.	0.4	13
108	Clinical Correlation of CD4+CD25+ Regulatory T Cells in Early Immune Reconstitution after Myeloablative Allogeneic Stem Cell Transplantation. <i>Chonnam Medical Journal</i> , 2009, 45, 154.	0.1	0

#	ARTICLE	IF	CITATIONS
109	Polymyositis and myocarditis after donor lymphocyte infusion. <i>International Journal of Hematology</i> , 2009, 90, 113-116.	1.6	14
110	The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2009, 88, 425-432.	1.8	28
111	The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. <i>Leukemia Research</i> , 2009, 33, 665-670.	0.8	62
112	Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell Lymphoma, Unspecified: Complete Remission at Transplantation and the Prognostic Index of Peripheral T Cell Lymphoma Are the Major Factors Predictive of Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 118-125.	2.0	49
113	Alpha-Type 1-Polarized Dendritic Cells Pulsed with Apoptotic Allogeneic Myeloma Cell Line Could Induce the Strong CTL Responses against Autologous Myeloma Cells.. <i>Blood</i> , 2009, 114, 4931-4931.	1.4	0
114	Efficacy and Safety of Micafungin as An Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases.. <i>Blood</i> , 2009, 114, 4661-4661.	1.4	0
115	Relapsed Marginal Zone B-Cell Lymphoma: Clinical Features and Treatment Outcome.. <i>Blood</i> , 2009, 114, 5017-5017.	1.4	0
116	Treatment Outcome of Steroid-Refractory Chronic Graft-Versus-Host Disease with Weekly Rituximab Followed by Maintenance Rituximab: a KSBMT Multicenter Phase II Study.. <i>Blood</i> , 2009, 114, 1151-1151.	1.4	0
117	Phase II Trial of 90y-Ibritumomab Tiuxetan Treatment as Consolidation After 6th R-CHOP Chemotherapy in Patients with Limited-Stage, Bulky Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2009, 114, 3751-3751.	1.4	1
118	Association Between Genetic Polymorphism in DNA Repair Genes and Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 4131-4131.	1.4	0
119	Comparing Standard IPI with Revised-IPI in Patients with Diffuse Large B-Cell Lymphoma: Which Has a More Differential Potential for Predicting the Outcomes after R-CHOP Chemotherapy.. <i>Blood</i> , 2008, 112, 2003-2003.	1.4	1
120	Central Nervous System Relapses in Patients with Diffuse Large B Cell Lymphoma: Multicenter Retrospective Analysis in Korea. <i>Blood</i> , 2008, 112, 5314-5314.	1.4	0
121	Polymorphisms in Myeloid Cell Leukemia-1 and the Risk for Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 3977-3977.	1.4	0
122	Treatment Outcome and Prognostic Factors in Patients with Precursor B and T Lymphoblastic Lymphoma. <i>Blood</i> , 2008, 112, 3601-3601.	1.4	20
123	GST T1 and GST M1 Polymorphisms Are Associated with the Risk of Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 3978-3978.	1.4	0
124	Statistical Correlations Between Quantifiable Disease Variables and Prognosis in Hematological Malignancy Patients Treated with Itraconazole as An Empirical Antifungal Therapy: A Prospective Multicenter Observational Study in Korea. <i>Blood</i> , 2008, 112, 4028-4028.	1.4	16
125	Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2007, 82, 1-5.	4.1	51
126	No Reversal of Demethylation after Azacitidine Treatment in Concordance with Poor Clinical Response.. <i>Blood</i> , 2007, 110, 4629-4629.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Clinical Usefulness and Therapeutic Plan with Interim PET/CT Analysis in Malignant Lymphoma.. Blood, 2006, 108, 2403-2403.	1.4	0
128	Clinical Correlation of Foxp3 Regulatory Gene Expressions and NK Cells in Early Engraftment after Myeloablative Allogeneic Stem Cell Transplantation.. Blood, 2006, 108, 2911-2911.	1.4	0
129	Predictable Prognostic Factor of CD56 Expression in Acute Myeloid Leukemia with t(8:21) Including Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2005, 106, 3288-3288.	1.4	0
130	Comparison of the Peripheral Blood Stem Cell Mobilization and Harvest after Each Consolidation Chemotherapy in Patients with Acute Myeloid Leukemia in First Complete Remission Who Underwent Autologous Stem Cell Transplantation.. Blood, 2005, 106, 5495-5495.	1.4	1
131	Methylenetetrahydrofolate Reductase and Methionine Synthase Polymorphism and Risk of Non-Hodgkin's Lymphoma.. Blood, 2005, 106, 4691-4691.	1.4	0
132	Modified Thalidomide, Cyclophosphamide and Dexamethasone (TCD) to Patients with Multiple Myeloma as Primary Therapy Prior to Peripheral Blood Stem Cell Collection.. Blood, 2005, 106, 5173-5173.	1.4	0
133	Clinical Significance of FLT3 Internal Tandem Duplication in Patients with Acute Myeloid Leukemia Who Underwent Allogeneic Bone Marrow Transplantation.. Blood, 2004, 104, 4419-4419.	1.4	0